Schizophrenia
Conditions
Interventions
Antipsychics Treatment:According to the recommendations in the "Guidelines for the Prevention and Treatment of Schizophrenia," the present study will use first-line antipsychotic medications: risperid
Sponsors
Peking University Sixth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for First-episode or Recurrent Untreated Schizophrenia (SCH) Patients: 1. Outpatients or inpatients with first-episode or recurrent untreated schizophrenia, meet the DSM-IV SCH diagnostic criteria. 2. Aged 18-55 years, with at least one guardian providing supervision within the past year. 3. No anticipated issues with relocation, transportation, or difficulty accessing treatment throughout the study. 4. Informed consent was obtained from both the patient and their guardian, with consent forms signed. Inclusion Criteria for Healthy Control Participants: 1. Physically healthy, screened using SCID with no Axis I disorder diagnosis according to DSM-IV; no history of mental illness. 2. No current physical illnesses. 3. Aged 18-55 years. 4. Matched with the patient group in terms of gender and education level. 5. Capable of completing the assessment content of the study, with informed consent. 6. No contraindications for MRI examination.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for First-episode or Recurrent Untreated Schizophrenia (SCH) Patients: 1. Presence of severe physical illnesses or substance abuse, including alcohol. 2. Severe physical disabilities that prevent follow-up. 3. Comorbid severe mental disorders, intellectual disability, dementia, or severe cognitive impairment. 4. Currently participating in or planning to participate in other clinical studies. Exclusion Criteria for Healthy Control Subjects: 1. History of substance dependence. 2. History of traumatic brain injury, epilepsy, or other organic brain diseases. 3. Presence of clearly diagnosed physical illnesses such as hypertension or diabetes. 4. Laboratory tests indicating liver or kidney dysfunction or other severe physical illnesses and metabolic disorders. 5. Pregnant or breastfeeding individuals.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale (PANSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impression Scale (CGI) ;MATRICS consensus cognitive battery, MCCB;Treatment Emergent Symptom Scale, TESS;Personal and Social Performance Scale, PSP; | — |
Countries
China
Contacts
Public ContactWeihua Yue
Peking University Sixth Hospital
Outcome results
None listed